戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ifically enriched according to the size of a uterine fibroid.
2 medical history was notable only for a large uterine fibroid.
3 preserved bone mineral density in women with uterine fibroids.
4 among women reporting both endometriosis and uterine fibroids.
5  with birth weight, gestational duration and uterine fibroids.
6 possibly pose a health hazard for women with uterine fibroids.
7 e observed clinical efficacy of EGCG against uterine fibroids.
8 ith placebo for the treatment of symptomatic uterine fibroids.
9 s regarding the molecular characteristics of uterine fibroids.
10  shows a modestly enlarged uterus with three uterine fibroids.
11   HIFU provides an excellent option to treat uterine fibroids.
12 s effective and safe in treating symptomatic uterine fibroids.
13 stream regulator REST in the pathogenesis of uterine fibroids.
14 KT-mTOR) pathway] is aberrantly expressed in uterine fibroids.
15 use model for a gene that is misexpressed in uterine fibroids.
16 tracellular matrix deposition, a hallmark of uterine fibroids.
17 ucing heavy menstrual bleeding in women with uterine fibroids.
18 cretion of the 2 collections and the risk of uterine fibroids.
19 tissue after focused ultrasound treatment of uterine fibroids.
20  heparin might be useful in the treatment of uterine fibroids.
21 tanding of the molecular basis of the common uterine fibroids.
22 mmon non-Mendelian manifestation of isolated uterine fibroids.
23 t properties, is an investigational drug for uterine fibroids.
24 racellular matrix, which is a key feature of uterine fibroids.
25 we implemented GDEC on the scRNA-seq data of uterine fibroids.
26 hes for prevention and medical management of uterine fibroids.
27 icipants were disproportionately affected by uterine fibroids.
28 elopment of long-term hormonal therapies for uterine fibroids.
29 higher positive predictive values (PPVs) for uterine fibroids (0.86 and 0.87 vs. 0.78) and for endome
30 o-controlled, 6-month phase 3 trials (Elaris Uterine Fibroids 1 and 2 [UF-1 and UF-2]) to evaluate th
31  this study was to identify risk factors for uterine fibroids among women undergoing tubal sterilizat
32 fant formula feeding and ultrasound-detected uterine fibroids among young African-American women with
33 CC is associated with clinically significant uterine fibroids and aggressive renal tumors.
34 ene is etiologically implicated in diabetes, uterine fibroids and cancer.
35 y embolization, in women who had symptomatic uterine fibroids and did not want to undergo hysterectom
36                                              Uterine fibroids and endometriosis may be associated wit
37 diagnostic information) to identify incident uterine fibroids and endometriosis patients among n=750
38  once daily, may have efficacy in women with uterine fibroids and heavy bleeding while avoiding hypoe
39 t of women aged 40 years with a diagnosis of uterine fibroids and no desire for future pregnancy was
40 ctively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids.
41 pments in drug delivery for the treatment of uterine fibroids and tumors of similar composition.
42 59 women (mean age, 35.9 years +/- 4.8) with uterine fibroids and/or adenomyosis who were unable to c
43 justed for age, BMI, race, family history of uterine fibroids, and isoflavone excretion, this trend r
44 I 25-29.9 kg/m(2), asthma, thrombocytopenia, uterine fibroids, antidepressant use, induction of labou
45                                              Uterine fibroids are a common cause of heavy menstrual b
46                                              Uterine fibroids are an understudied condition, with ear
47                                              Uterine fibroids are benign tumors that can cause severe
48                                              Uterine fibroids are common non-cancerous neoplasm that
49                                              Uterine fibroids are common tumors that can cause heavy
50                                    In women, uterine fibroids are highly prevalent estrogen-responsiv
51                                              Uterine fibroids are hormonally responsive; estradiol an
52                                              Uterine fibroids are hormone-responsive neoplasms that a
53                          Eligible women with uterine fibroid-associated heavy menstrual bleeding (men
54 suppresses gonadal steroids and might reduce uterine-fibroid-associated signs.
55                                Utilities for uterine fibroids before and after treatment were obtaine
56 tal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain.
57 ide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear.
58                                              Uterine fibroids, benign tumors of the smooth muscle lay
59 esized to be risk factors for development of uterine fibroids, but few studies have investigated the
60 ight urine collections (48 h apart) from 170 uterine fibroid cases and 173 controls were analyzed for
61 Is) have been hypothesized to play a role in uterine fibroid development.
62                     Two readers compared the uterine fibroid, dominant (ie, largest) fibroid, and per
63 visualization at aortography performed after uterine fibroid embolization (UFE) and, using OA arterio
64                                              Uterine fibroid embolization (UFE) is a minimally invasi
65 egnancy rates after conventional and partial uterine fibroid embolization (UFE).
66 ber 1, 2010, and December 27, 2010, prior to uterine fibroid embolization.
67 epatic chemoembolization for cancer; and 60, uterine fibroid embolization.
68 tudied in 76 consecutive patients undergoing uterine fibroid embolization.
69 ers and diseases (polycystic ovary syndrome, uterine fibroids, endometriosis) as well as contraceptio
70 rders of the female genital tract, including uterine fibroids, endometriosis, or ovarian cysts.
71                      Continued validation of uterine fibroids/endometriosis EHR studies is warranted
72  and illustrate the methodology by analyzing uterine fibroid gene expression data.
73                          Our analysis of the uterine fibroid growth gene expression data suggests tha
74 amycin (mTOR) pathway in the pathogenesis of uterine fibroids has been suggested in several studies.
75 ndometriosis, polycystic ovary syndrome, and uterine fibroids-have remained stubbornly understudied d
76 n was found between isoflavone excretion and uterine fibroids; however, the intake of soy foods, the
77 E significantly improves symptoms related to uterine fibroids in 85%-90% of patients.
78  follicle, can be associated with the common uterine fibroids in a syndrome called multiple cutaneous
79 t pattern, manifesting as skin leiomyoma and uterine fibroids in affected individuals.
80 ion for the chronic treatment of symptomatic uterine fibroids in women who cannot or do not want to t
81 sure has been shown in Eker rats to increase uterine fibroid incidence in adulthood.
82                                The growth of uterine fibroids is sex hormone-dependent and commonly a
83                                              Uterine fibroids (leiomyomas) are a major women's health
84                                              Uterine fibroids (leiomyomas) are the most common tumors
85                                              Uterine fibroids (leiomyomas) have historically been vie
86                                              Uterine fibroids (leiomyomas), the most common tumors in
87 ose a unifying mechanism for pathogenesis of uterine fibroids mediated by H19 and identify a pathway
88  of Ms P, a 41-year-old woman with recurrent uterine fibroids, menorrhagia, anemia, and fatigue who w
89    Women with a history of endometriosis and uterine fibroids might have an increased long term risk
90        Already approved for the treatment of uterine fibroids, MRgFUS is in ongoing clinical trials f
91 9 or 1985-1987) or who reported a history of uterine fibroids (n = 317).
92 ptor site near a polypyrimidine tract, and a uterine fibroid obtained from a patient showed loss of h
93                                              Uterine fibroids occur in approximately 50% of women ove
94 ere virtually unchanged after adjustment for uterine fibroids or endometriosis history.
95 mon conditions that lead to surgery, such as uterine fibroids or endometriosis.
96        Risk was marginally related to having uterine fibroids (OR=0.6, 95% CI: 0.5, 1.0) and long-ter
97 o differences in breast fibrocystic disease, uterine fibroids, or endometrial lining thickness as ass
98 quence of AP-1 loss on gene transcription in uterine fibroids remains poorly understood.
99 ignan-containing foods on the development of uterine fibroids remains to be determined.
100 on (-$30,850; 95% CI, -$31,629 to -$30,091), uterine fibroid resection (-$1509; 95% CI, -$1754 to -$1
101 erence, -37.7 days; 95% CI, -41.1 to -34.3), uterine fibroid resection (mean difference, -11.7 days;
102 presence of an IGF-I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.
103 l study was to evaluate the relation between uterine fibroid risk and phytoestrogen exposure.
104 d economic disadvantage ("disadvantage") and uterine fibroid risk is understudied.
105 rse association between lignan excretion and uterine fibroid risk.
106 o-megabase interval spanning FH in the NIEHS Uterine fibroid study, a cross-sectional study of fibroi
107  effects on the molecular pathways linked to uterine fibroids, such as re-establishing normal ovarian
108 health-related quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) qu
109                                              Uterine fibroids, the most common type of tumor among wo
110        This study intended to review HIFU in uterine fibroid therapy, to evaluate the role of HIFU in
111                                In women with uterine fibroids, there is a significant association bet
112                 Among women with symptomatic uterine fibroids, those who underwent myomectomy had a b
113                TBBPA can promote fibrosis in uterine fibroid through TGFB/SMAD signaling.
114                                              Uterine fibroid treatment using HIFU was effective and s
115                                              Uterine fibroid (UF) driver mutations in Mediator comple
116                                Nearly 70% of Uterine fibroid (UF) tumors are driven by recurrent MED1
117 ciation between atrial fibrillation (AF) and uterine fibroids (UF) is unclear, though UF are linked t
118 enetically (ORs = 1.06-2.09) associated with uterine fibroids (UF), PCOS, heavy menstrual bleeding (H
119                                              Uterine fibroids (UF), that can disrupt normal uterine f
120                                              Uterine fibroids (UFs) are associated with irregular or
121 ecords (EHRs) present opportunities to study uterine fibroids uterine fibroids and endometriosis with
122 e of FH and the linked genes in nonsyndromic uterine fibroids, we explored a two-megabase interval sp
123 Cases comprised women aged 17-44 years whose uterine fibroids were first visualized at the time of tu
124         Ultrasound or hysterectomy confirmed uterine fibroids were not associated with all cause prem
125                                              Uterine fibroids were used as a perfusion model.
126           Adult patients with a diagnosis of uterine fibroids who underwent hysterectomy, myomectomy,
127 fective outpatient procedures for women with uterine fibroids who want to conceive.
128 om normally cycling premenopausal women with uterine fibroids, who were not on hormonal treatment at
129              The trend for a reduced risk of uterine fibroids with increasing quartiles of lignan exc
130 ing to joint categories of endometriosis and uterine fibroids, with an increased risk of all cause pr

 
Page Top